Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Hypofractionated Chest Radiotherapy · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Hypofractionated Chest Radiotherapy | RADIATION | Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks. |
Inclusion Criteria: * limited stage small cell lung cancer * adequate pulmonary function test (FEV1 \>1.0 L, DLCO \>50%) * signed study consent * age at least 18 years * Karnofsky performance status as least 70% * eligible to receive standard concurrent small cell cancer chemotherapy Exclusion Cri...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
Hypofractionated Chest Radiotherapy is an investigational radiation therapy being studied for the treatment of lung neoplasms, specifically limited stage small cell lung cancer. It delivers higher doses of radiation over fewer sessions compared to conventional radiotherapy. The therapy is currently in clinical development and is not yet approved by regulatory authorities.
Hypofractionated Chest Radiotherapy is being developed by Avalon GloboCare Corp., a biopharmaceutical company traded on the stock exchange under the ticker symbol ALBT. The company is conducting clinical research to evaluate the safety and efficacy of this radiation therapy approach for patients with lung cancer.
Hypofractionated Chest Radiotherapy is in Phase 2 clinical development. It is an investigational therapy, meaning it has not received regulatory approval and is still being evaluated in clinical trials. The Phase 2 study has been completed, and the therapy remains under investigation for its potential use in treating lung neoplasms.
Hypofractionated Chest Radiotherapy has been studied in one clinical trial registered as NCT00907569, titled 'Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer.' This Phase 2 study was conducted in Canada and enrolled 2 participants aged 18 years and older. The trial has been completed.
Hypofractionated Chest Radiotherapy is a specific approach to radiation therapy that uses larger doses per treatment session with fewer total sessions compared to conventional radiation therapy. It is being studied specifically for limited stage small cell lung cancer. The therapy is distinct in its dosing schedule and is under clinical investigation.